
The U.S. Food and Drug Administration (FDA) on Thursday informed Aquestive Therapeutics, Inc. (NASDAQ:AQST) that an advisory committee meeting is not required for Anaphylm (dibutepinephrine) Sublingual Film.
The Prescription Drug User Fee Act (PDUFA) target action date for Anaphylm remains January 31, 2026.